$7.05
-0.27[-3.69%]
At close: Apr 26
$7.05
0[0.00%]
After Hours: 7:30PM EDT
Avid Bioservices
(NASDAQ:CDMO)Avid Bioservices Stock (NASDAQ:CDMO), Analyst Ratings, Price Targets, Predictions
Avid Bioservices Inc has a consensus price target of $9.8, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from Stephens & Co., RBC Capital, and RBC Capital on March 11, 2024, March 7, 2024, and December 8, 2023. With an average price target of $8.67 between Stephens & Co., RBC Capital, and RBC Capital, there's an implied 22.93% upside for Avid Bioservices Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
RBC Capital
Craig-Hallum
Keybanc
William Blair
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Avid Bioservices
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/11/2024 | CDMO | Buy Now | Avid Bioservices | $7.05 | 70.21% | Stephens & Co. | Jacob Johnson | $15 → $12 | Maintains | Overweight | Get Alert |
| 03/07/2024 | CDMO | Buy Now | Avid Bioservices | $7.05 | -0.71% | RBC Capital | Sean Dodge | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 12/08/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | -0.71% | RBC Capital | Sean Dodge | $15 → $7 | Maintains | Outperform | Get Alert |
| 12/08/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 126.95% | Craig-Hallum | Matt Hewitt | $22 → $16 | Maintains | Buy | Get Alert |
| 12/08/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 98.58% | Keybanc | Paul Knight | $20 → $14 | Maintains | Overweight | Get Alert |
| 09/28/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | — | William Blair | Max Smock | — | Initiates | → Market Perform | Get Alert |
| 09/08/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 112.77% | RBC Capital | Sean Dodge | $17 → $15 | Maintains | Outperform | Get Alert |
| 06/22/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 141.13% | RBC Capital | Sean Dodge | $20 → $17 | Maintains | Outperform | Get Alert |
| 06/22/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 183.69% | Stephens & Co. | Jacob Johnson | → $24 | Reiterates | Overweight → Overweight | Get Alert |
| 03/14/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 212.06% | Stephens & Co. | Jacob Johnson | → $22 | Reiterates | → Overweight | Get Alert |
| 03/14/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 183.69% | RBC Capital | Sean Dodge | → $20 | Reiterates | → Outperform | Get Alert |
| 03/14/2023 | CDMO | Buy Now | Avid Bioservices | $7.05 | 183.69% | Keybanc | Paul Knight | → $20 | Upgrade | Sector Weight → Overweight | Get Alert |
| 12/07/2022 | CDMO | Buy Now | Avid Bioservices | $7.05 | 183.69% | RBC Capital | Sean Dodge | $22 → $20 | Maintains | Outperform | Get Alert |
| 06/30/2022 | CDMO | Buy Now | Avid Bioservices | $7.05 | 212.06% | RBC Capital | Sean Dodge | $32 → $22 | Maintains | Outperform | Get Alert |
| 03/09/2022 | CDMO | Buy Now | Avid Bioservices | $7.05 | 297.16% | Stephens & Co. | Jacob Johnson | $31 → $28 | Maintains | Overweight | Get Alert |
| 12/08/2021 | CDMO | Buy Now | Avid Bioservices | $7.05 | 396.45% | Craig-Hallum | Matt Hewitt | — | Maintains | Buy | Get Alert |
| 12/08/2021 | CDMO | Buy Now | Avid Bioservices | $7.05 | 353.9% | RBC Capital | Sean Dodge | — | Maintains | Outperform | Get Alert |
| 12/08/2021 | CDMO | Buy Now | Avid Bioservices | $7.05 | — | Keybanc | Paul Knight | — | Downgrade | Overweight → Sector Weight | Get Alert |
| 06/30/2021 | CDMO | Buy Now | Avid Bioservices | $7.05 | 311.35% | Craig-Hallum | Matt Hewitt | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Avid Bioservices (CDMO)?
The latest price target for Avid Bioservices (NASDAQ: CDMO) was reported by Stephens & Co. on March 11, 2024. The analyst firm set a price target for $12.00 expecting CDMO to rise to within 12 months (a possible 70.21% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avid Bioservices (CDMO)?
The latest analyst rating for Avid Bioservices (NASDAQ: CDMO) was provided by Stephens & Co., and Avid Bioservices maintained their overweight rating.
When was the last upgrade for Avid Bioservices (CDMO)?
The last upgrade for Avid Bioservices Inc happened on March 14, 2023 when Keybanc raised their price target to $20. Keybanc previously had a sector weight for Avid Bioservices Inc.
When was the last downgrade for Avid Bioservices (CDMO)?
The last downgrade for Avid Bioservices Inc happened on December 8, 2021 when Keybanc changed their price target from N/A to N/A for Avid Bioservices Inc.
When is the next analyst rating going to be posted or updated for Avid Bioservices (CDMO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avid Bioservices, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avid Bioservices was filed on March 11, 2024 so you should expect the next rating to be made available sometime around March 11, 2025.
Is the Analyst Rating Avid Bioservices (CDMO) correct?
While ratings are subjective and will change, the latest Avid Bioservices (CDMO) rating was a maintained with a price target of $15.00 to $12.00. The current price Avid Bioservices (CDMO) is trading at is $7.05, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.